Zeal Healthcare ha compartido esto
The biosimilars market is experiencing remarkable growth, with projections indicating a significant expansion from $29.4 billion in 2023 to $66.9 billion by 2028, with a CAGR of 17.8% (Markets and Markets, 2023). This is being driven by an increasing demand for cost-effective treatments, the expiration of patents on major biologics, rising prevalence of chronic diseases, and regulatory support (Delveinsight, 2021). At RTM Healthcare Group, we share the vision of making advanced treatments accessible across regions; in line with the growth of the biosimilars market, we were present at Biosimilars LATAM - Mexico 2024, with the participation of our CEO Raman Wattamwar, who spoke about the growth opportunities of this industry and the access of biosimilars globally, especially in emerging markets, and the Impact of Biosimilar Licenses on Pharmaceutical Innovation. Video retrieved from: https://lnkd.in/e-ZTEch4 JackLeckerman #Biosimilars #Pharmaceuticals #HealthcareInnovation #BiosimilarsLatamMexico2024 #EnhancingAccess